SCHEMBL1504248

SCHEMBL1504248

O=C(O)c1nc(=O)c2cc(Cl)ccc2[nH]1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.48
KMT2A Q03164 4/20 0.48
KDM4E B2RXH2 3/20 0.48
MAP2 P11137 3/20 0.48
CASP1 P29466 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
HSD17B10 Q99714 1/20 0.48
F7 P08709 2/20 0.47
F3 P13726 2/20 0.47
CA12 O43570 1/20 0.45
CA9 Q16790 1/20 0.45
LMNA P02545 2/20 0.45
HPGD P15428 2/20 0.44
CYP2C9 P11712 1/20 0.44
MAPK1 P28482 1/20 0.44
BLM P54132 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44
CYP1A2 P05177 1/20 0.44
GAA P10253 1/20 0.44
ALDH1A1 P00352 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30629476 0.82 NR4A2 (0.51) MEN1KMT2AKDM4EMAP2NPSR1
SCHEMBL26632743 0.82 NR4A2 (0.51) MEN1KMT2AKDM4EMAP2NPSR1
SCHEMBL30918933 0.80 LMNA (0.53) MEN1KMT2AKDM4ECASP1NPSR1
SCHEMBL1503884 0.79 ALDH1A1 (0.54) HPGDCYP1A2GAAALDH1A1
SCHEMBL523253 0.79 RHEB (0.54) MEN1KMT2AKDM4ENPSR1F7
SCHEMBL30558024 0.77 KDM4E (0.50) MEN1KMT2AKDM4EHSD17B10LMNA
SCHEMBL14247484 0.77 KDM4E (0.50) MEN1KMT2AKDM4EHSD17B10LMNA
SCHEMBL13343598 0.76 KDM4E (0.57) MEN1KMT2AKDM4EHSD17B10HPGD
SCHEMBL523254 0.76 PIN1 (0.66) MEN1KMT2AKDM4EHSD17B10HPGD
SCHEMBL5313770 0.76 LMNA (0.57) MEN1KMT2AKDM4ECASP1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250027223-A1 ELECTRODEPOSITION OF MOLYBDENUM DISULFIDE DRY FILM LUBRICANT COATINGS GM Global Technology Operations LLC 2025-01-23 US disclosed
CN-119332321-A Electrodeposition of molybdenum disulfide dry film lubricant coatings 通用汽车环球科技运作有限责任公司 2025-01-21 CN disclosed
EP-1405852-B9 DIAMINE DERIVATIVES DAIICHI SANKYO CO LTD (JP) 2013-03-27 EP disclosed
CN-1826333-B Diamine derivatives DAIICHI SANKYO CO LTD 2012-12-26 CN disclosed
EP-1577301-B1 Antithrombotic diaminocyclohexane derivatives DAIICHI SANKYO CO LTD (JP) 2012-09-12 EP disclosed
EP-1405852-B1 DIAMINE DERIVATIVES DAIICHI SANKYO CO LTD (JP) 2012-08-01 EP disclosed
US-20110312990-A1 Diamine Derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-12-22 US disclosed
US-20110312990-A1 Diamine Derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-12-22 US disclosed
US-20110312990-A1 Diamine Derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-12-22 US disclosed
EP-2343290-A1 Diamine derivatives as factor X inhibitors Daiichi Sankyo Company, Limited (JP) 2011-07-13 EP disclosed
CN-1894238-A Diamine derivatives DAIICHI SEIYAKU CO (JP) 2007-01-10 CN disclosed
US-20060252837-A1 Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-11-09 US disclosed
CN-1826333-A Diamine derivatives DAIICHI SEIYAKU CO (JP) 2006-08-30 CN disclosed
CN-1751025-A Diamine derivatives DAIICHI SEIYAKU CO (JP) 2006-03-22 CN disclosed
US-20050245565-A1 Diamine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-11-03 US disclosed
EP-1577301-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-09-21 EP disclosed
US-20050119486-A1 Diamine derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2005-06-02 US disclosed
US-20050020645-A1 Diamine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-01-27 US disclosed
EP-1415992-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-05-06 EP disclosed
EP-1405852-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-04-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060252837-A1 Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X F2, C1S, C9 MEN1 726/4885KMT2A 3495/4885KDM4E 3761/4885
US-20050020645-A1 Diamine derivatives C9, C1S, C1R MEN1 457/4885KMT2A 3485/4885KDM4E 3971/4885
US-20050245565-A1 Diamine derivatives C9, C1S, C1R MEN1 457/4885KMT2A 3485/4885KDM4E 3971/4885
US-20050119486-A1 Diamine derivatives C9, C1S, C1R MEN1 457/4885KMT2A 3485/4885KDM4E 3971/4885
US-20110312990-A1 Diamine Derivatives C9, C1S, C1R MEN1 602/4885KMT2A 3461/4885KDM4E 3759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.